Activating mutations in the RAS family or BRAF frequently occur in many types of human cancers but are rarely detected in breast tumors. However, activation of the RAS-RAF-MEK-ERK MAPK pathway is commonly observed in human breast cancers, suggesting that other genetic alterations lead to activation of this signaling pathway. To identify breast cancer oncogenes that activate the MAPK pathway, we screened a library of human kinases for their ability to induce anchorageindependent growth in a derivative of immortalized human mammary epithelial cells (HMLE). We identified p21activated kinase 1 (PAK1) as a kinase that permitted HMLE cells to form anchorage-independent colonies. PAK1 is amplified in several human cancer types, including 30-33% of breast tumor samples and cancer cell lines. The kinase activity of PAK1 is necessary for PAK1-induced transformation. Moreover, we show that PAK1 simultaneously activates MAPK and MET signaling; the latter via inhibition of merlin. Disruption of these activities inhibits PAK1-driven anchorage-independent growth. These observations establish PAK1 amplification as an alternative mechanism for MAPK activation in human breast cancer and credential PAK1 as a breast cancer oncogene that coordinately regulates multiple signaling pathways, the cooperation of which leads to malignant transformation.
Introduction
The RAS family of small GTPases, HRAS, KRAS and NRAS, are often mutated in human cancers, rendering them constitutively active and oncogenic (reviewed in Lau and Haigis, 2009) . Oncogenic mutations in the RAS family genes are common in selected cancer types, including pancreatic, colon and non-small-cell lung cancers. RAS activation may occur directly through these oncogenic mutations or indirectly due to activation of RAS regulators or effectors (reviewed in Downward, 2003) . Activation of growth factor signaling is a predominant mechanism upstream of RAS that leads to its activation. In epithelial cancers, EGFR and ERBB2-two ErbB family tyrosine kinase (TK) receptors-commonly activate RAS oncogenic function (Mendelsohn and Baselga, 2000) . Similarly, loss of function of a RAS-GAP, neurofibromatosis type 1 (NF1), also drives RAS downstream signaling (Bollag et al., 1996) .
Several alternate mechanisms that activate RAS signaling have also been previously described. The RAS effector pathway, PI3K, is activated by mutations of its catalytic subunit PIK3CA, amplification of its downstream target AKT or loss of function of PTEN , a negative regulator (Scheid and Woodgett, 2001) . Similarly, activating mutation of BRAF occurs in 50% of melanomas, leading to constitutive activation of MAPK signaling (Davies et al., 2002) . These two effector pathways have important roles in RAS-mediated cell transformation, as co-inhibition of PI3K and MAPK efficiently suppresses RAS-driven tumor growth (Engelman et al., 2008; Sos et al., 2009) .
Less than 5% of human breast tumors exhibit oncogenic mutations in the RAS family of genes (Miyakis et al., 1998; Lau and Haigis, 2009) . RAS signaling in breast cancer is more commonly activated by alterations upstream or downstream of RAS itself. For example, the RAS pathway is activated through ERBB2 amplification in about 20% of breast tumors (Hynes and MacDonald, 2009) . Such growth factor activation in breast cancer results in a co-activation of RAS effectors PI3K and MAPK (Neve et al., 2002) . Co-inhibition of these synergistic pathways has proven more effective than single-pathway inhibition for suppression of breast tumorigenesis (Hoeflich et al., 2009; Mirzoeva et al., 2009) . Moreover, co-activation of these RAS effectors is common in breast cancer. Activating mutations in PIK3CA are found in 25-30% of breast tumors, whereas loss of function of PTEN by mutation or loss of protein activates the PI3K pathway in 5-30% of human breast tumors (Freihoff et al., 1999; Bachman et al., 2004; Hennessy et al., 2005; Miron et al., 2010) . In contrast, oncogenic mutations in the MAPK pathway components have not been reported in breast tumors. Therefore, alternative mechanisms that activate MAPK signaling to promote breast oncogenesis need to be defined.
To identify genes that activate or substitute for MAPK activation in breast cancer, we performed a kinase-focused screen in a human mammary epithelial cell transformation model (HMLE) driven by oncogenic RAS. Expression of oncogenic HRAS (HRAS V12 ) in HMLE cells, which are immortalized with the catalytic subunit of telomerase and SV40 early region, promotes anchorage-independent growth and tumorigenesis (Elenbaas et al., 2001) . In this transformation model, simultaneous expression of myristoylated (myr)-AKT1 and an activated allele of MEK1 (MEK1 S218D/S222D , MEK DD ) can substitute for oncogenic HRAS. Using HMLE cells expressing MEK DD , we previously found IKBKE as a kinase oncogene amplified in 30% of human breast cancers, and CSNK1E as a transforming gene that also functions as a synthetic lethal partner with activated b-catenin (Boehm et al., 2007; Kim et al., 2010) . To identify genes that activate MAPK signaling and cooperate with active PI3K pathway, we screened for oncogenes in HMLE cells expressing myr-AKT1 (HMLEA). We identified p21-activated kinase 1 (PAK1) as an amplified kinase capable of inducing potent mammary cell transformation through the coordinate regulation of MAPK and MET signaling.
Results
Kinome focused gain-of-function screen for kinases that promote anchorage-independent growth of immortalized HMLE cells To identify oncogenes that activate the MAPK pathway in mammary epithelial cells, we expressed an open reading frame (ORF) library composed of kinases in HMLEA cells. Specifically, we pooled 597 myristoylation-and Flag-epitope-tagged kinases, introduced them into HMLEA cells and measured anchorage-independent growth (Figure 1a ). Macroscopic colonies formed by HMLEA cells expressing kinase pools or controls were counted at 2 weeks. We found that pool no. 9 formed numerous colonies ( Figure 1b ). When the 27 kinases in pool no. 9 were individually tested for anchorage-independent growth of HMLEA cells, we found that PAK1 induced robust colony formation ( Figure 1c ). We also observed that myristoylation of PAK1 was unnecessary to induce anchorage-independent growth (Supplementary Figure 1A) , and we used non-myristoylated PAK1 for subsequent validation and characterization studies. Moreover, expression of PAK1 sufficed to induce anchorage-independent growth of HMLE cells (Figure 1d ). Thus, our observations establish that PAK1 can transform immortalized HMLE cells, unlike prior studies carried out in breast cancer cell lines, where PAK1 enhanced anchorageindependent colony formation (Vadlamudi et al., 2000) . Our findings in HMLEA cells indicate that PAK1 also cooperates with other oncogenic alterations to induce cell transformation.
PAK1 amplifications in human breast cancer
The observation that PAK1 induces cell transformation suggested that PAK1 could function as an oncogene. To assess the frequency of PAK1 amplification in human cancer, we analyzed a large set of human cancer samples in Tumorscape, a dataset that includes whole-genome analyses of somatic copy number alterations in a collection of 3131 human samples, including 243 breast tumor samples and cancer cell lines (Beroukhim et al., 2010) . We found that PAK1 is amplified in 33% of breast samples (Figure 2a ), as well as in a smaller fraction of non-small-cell lung, ovarian, small-cell lung, melanoma and esophageal squamous cancers. These findings confirm and extend smaller scale studies that focused on chromosome 11q13, mainly, but not exclusively, in ovarian cancer (Bekri et al., 1997; Schraml et al., 2003; Lambros et al., 2005; Kim et al., 2006; Bostner et al., 2007; Brown et al., 2008; Chattopadhyay et al., 2010; Tu et al., 2011) . Overall, we found that 16% of all cancers in the Tumorscape exhibited amplification of the locus that contains PAK1.
To confirm that PAK1 amplifications occur in breast cancer, we performed fluorescence in situ hybridization (FISH) and found normal PAK1 copy number in breast cancer cell lines that did not show evidence of PAK1 amplification in Tumorscape (EFM19 and SKBR3). In contrast, when we examined metaphase spreads derived from breast cancer cell lines that exhibited amplification of PAK1 in Tumorscape (SUM52 and SUM190), we found clear evidence of PAK1 copy number gain ( Figure 2b ). The average number of PAK1 signals per nucleus was greater than the chromosome 11 centromere reference signals in SUM52 and SUM190 lines ( Figure 2c ). The PAK1 FISH signal in the four cell lines correlated with the corresponding PAK1 copy number in Tumorscape. Furthermore, PAK1 copy number directly correlated with its expression both at the RNA and protein levels in the four cell lines (Figure 2d ).
Using the genomic identification of significant targets in cancer (GISTIC) algorithm (Beroukhim et al., 2007) in Tumorscape samples, we found that PAK1 lies on an amplification peak on chromosome 11q distinct from a neighboring peak containing CCND1 (Figure 2e ). CCND1 is amplified in 42% of all samples in Tumorscape, whereas 43% of those that exhibit PAK1 amplification also carry CCND1 amplification. These observations strongly suggest that amplifications of PAK1 and CCND1 are independent events.
We also analyzed The Cancer Genome Atlas (TCGA) for PAK1 copy number gain in human cancer samples. We found that 30% of breast invasive adenocarcinoma samples showed significant PAK1 amplification (Qvalue 8.04E-39). Together, our observations establish that PAK1 is amplified in a significant fraction of human breast tumors and tumor-derived cell lines.
We then investigated whether cell lines that harbor PAK1 amplifications were dependent on PAK1 for proliferation or anchorage-independent colony formation. We failed to find changes in population-doubling times of SUM52 cells expressing PAK1-or lacZ-specific short hairpin RNAs (shRNAs) or in HMLE cells expressing control vector or PAK1, indicating that PAK1 expression level does not affect proliferation ( Figure 3a ). In contrast, suppression of PAK1 by two different PAK1-specific shRNAs in SUM52 and SUM190 lines compromised anchorage-independent growth ( Figure 3b ). Importantly, in cell lines (SKBR3 and EFM19) that do not harbor PAK1 amplification, suppression of PAK1 failed to affect anchorage-independent growth (Figure 3c ). These observations demonstrate that cell lines that exhibit amplification and overexpression of PAK1 depend on it for anchorage-independent growth, strongly indicating that PAK1 is a targeted gene in the more-telomeric 11q GISTIC amplification peak in Tumorscape.
PAK1 kinase activity in anchorage-independent growth PAK1 regulates signaling pathways through both kinase-dependent and kinase-independent mechanisms (reviewed in Dummler et al., 2009) . We evaluated the requirement for PAK1 kinase activity in cell transformation by expressing wild-type PAK1 and its previously characterized kinase-deficient mutant, PAK1 K299R (Tang et al., 1997) . We found that wild-type PAK1, but not PAK1 K299R , formed robust anchorage-independent colonies in HMLE cells (Figure 4a ).
Prior work has shown that the kinase activity of PAK1 can be assessed by the status of phosphorylation at several internal sites. PAK1 phosphorylation at T423 relieves autoinhibitory conformation, allowing autophosphorylation at S144 to maintain kinase activity (reviewed in Bokoch, 2003) . We evaluated the effect of overexpressing PAK1 on its kinase activity by assessing the phosphorylation status of PAK1 itself as well as its reported phosphorylation targets. When we expressed a control vector, PAK1 or PAK1 K299R in HMLE cells, we found that wild-type PAK1 but not PAK1 K299R was phosphorylated at both T423 and S144 sites ( Figure 4b ). However, comparison of total and phosphorylated PAK1 levels indicates that a fraction of PAK1 in HMLE-PAK1 cells may remain in an autoinhibitory conformation. Nevertheless, we found that the phosphorylation levels of three PAK1-specific substrates; RAF1 S338 , MEK1 S298 and merlin S518 , were enhanced in HMLE-PAK1 cells ( Figure 4c ; Coles and Shaw, 2002; Xiao et al., 2002; Zang et al., 2002; Zang et al., 2008) . The elevated phosphorylation levels of PAK1 itself as well as its substrates exclusively in HMLE-PAK1 cells confirm that a greater portion of the wild-type PAK1 is in its active conformation, and hence catalytically active compared to PAK1 K299R . These findings establish that the kinase activity of PAK1 is necessary for the transformation of mammary epithelial cells. Moreover, PAK1-induced phosphorylation of RAF1, MEK1 and merlin suggests that these pathways may contribute to PAK1-driven transformation. 
MAPK signaling and PAK1-driven anchorageindependent growth
Phosphorylation of RAF1 S338 and MEK1 S298 prime the activation of the MAPK pathway by facilitating phosphorylation of MEK1 at its activation loop, and subsequent phosphorylation of ERK1/2. PAK1 expression in HMLE cells not only increased phosphorylation of RAF1 S338 and MEK1 S298 , two critical upstream members of the MAPK pathway, but also increased phosphorylation of the downstream effectors, ERK1/2 T202/Y204 ( Figures  4c and 5a ). Conversely, suppression of PAK1 in SUM52 repressed phosphorylation of RAF1 S338 and ERK1/2 T202/Y204 , thus indicating regulation of the MAPK pathway by PAK1 ( Supplementary Figure 2A ). In consonance with this observation, suppressing RAF1 in two PAK1-dependent cell lines, HMLE-PAK1 and SUM52, suppressed phospho-ERK1/2 levels and compromised anchorage-independent growth (Supplementary Figure 2B ; Figure 5b ). Furthermore, when we treated SUM52 and EFM19 with U0126, a MEK1/2specific inhibitor (Favata et al., 1998) , SUM52 formed dramatically fewer colonies, whereas EFM19 cells, which exhibit no PAK1 copy number gain, were largely unaffected ( Figure 5c ). We also found that U0126 inhibited ERK1/2 T202/Y204 phosphorylation as well as the ability of HMLE cells expressing PAK1 or HRAS V12 (HMLER) to form colonies in a dose-dependent manner (Figure 5c ). Together, these genetic and pharmacological studies indicate that the activation of RAF-MEK-ERK MAPK signaling is essential for PAK1-induced anchorage-independent growth.
Prior work has implicated PAK1 in the regulation of RAS signaling. Even in the presence of oncogenic RAS, loss of PAK1 function or inhibition of PAK1 activators inhibited colony formation (Tang et al., 1997; Appledorn et al., 2010) . Similarly, we found that PAK1 suppression by shRNAs partially inhibited anchorageindependent growth of HMLER cells, reinforcing the role of PAK1 in RAS-driven transformation ( Figure  5d ). We, however, did not observe any difference in total or phosphorylated levels of PAK1 between HMLE and HMLER cells (Supplementary Figure 3A) . Hence, we 
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Y Shrestha et al conclude that PAK1 gain of function activates MAPK pathway, a RAS effector, which is necessary for PAK1driven anchorage-independent growth. Moreover, amplification resulting in overexpression of PAK1 is an alternate mechanism by which MAPK signaling may be activated in human breast tumors that do not harbor activating mutations in components of the RAS-RAF-MEK-ERK MAPK pathway.
Merlin function in MET signaling and PAK1-mediated anchorage-independent growth Merlin or NF2 is a tumor suppressor gene deleted in a subset of patients with neurofibromatosis and is a known substrate of PAK1 (reviewed in McClatchey, 2007) . Merlin and PAK1 are involved in an inhibitory loop where merlin binds to the p21-binding domain of PAK1, inhibiting its activation and suppressing RASdependent transformation (Kissil et al., 2003; Hirokawa et al., 2004) . PAK1, on the other hand, phosphorylates merlin at S518, which induces translocation of merlin away from the membrane and inhibits its function (Shaw et al., 2001; Kissil et al., 2002; Xiao et al., 2002) .
To investigate whether PAK1 regulation of merlin contributes to mammary cell transformation, we examined the consequences of altering PAK1 or NF2 expression in HMLE cells and breast cancer cell lines. PAK1 expression in HMLE cells, under conditions that led to anchorage-independent growth, resulted in increased phosphorylation of merlin S518 (Figure 4a and c) . Conversely, suppression of PAK1 in SUM52 not only inhibited anchorage-independent growth but also suppressed merlin S518 phosphorylation (Figure 3b and 6a ). Furthermore, shRNA-mediated suppression of NF2 induced anchorage-independent growth of HMLE cells, indicating a tumor suppressive function of merlin in breast cancer (Figure 6b ). These observations demonstrate that PAK1 regulates merlin at an inhibitory phosphorylation site, and that suppression of merlin promotes transformation of immortalized mammary epithelial cells.
Merlin has recently been shown to negatively regulate EGFR internalization and signaling through membrane sequestration (Curto et al., 2007) . In particular, merlin activity at the membrane of confluent mouse embryonic fibroblasts resulted in a substantial downregulation of overall phosphotyrosine levels, whereas NF2 À/À mouse embryonic fibroblasts exhibited high phosphotyrosine levels, indicating that merlin regulates phosphotyrosine signaling (Curto et al., 2007) . To investigate the role of merlin in membrane receptor activity, we compared phosphotyrosine levels in HMLE cells expressing wildtype PAK1 or the kinase-inactive mutant PAK1 K299R . We found that wild-type but not the kinase-inactive mutant of PAK1 induced an increase in total phosphotyrosine levels (Figure 6c ). On the basis of this observation, we investigated EGFR phosphorylation status in HMLE-PAK1 cells compared with HMLE cells expressing either a control vector or PAK1 K299R and found only a small increase, if any, in phosphorylation of EGFR at sites that indicate its activation status, (Figure 6d ; Batzer et al., 1994; Yamauchi et al., 1997) . Additionally, suppression of EGFR in HMLE-PAK1 cells did not alter colony formation, indicating EGFR may not be the appropriate target of merlin inhibition in this context ( Supplementary Figure 4) . Prior work has indicated that NHERF1, the adaptor protein that interacts with merlin for EGFR inhibition, is not specific to EGFR and may associate with other growth factor receptors (reviewed in Weinman et al., 2006) . We thus postulated that receptor TKs other than EGFR may be affected by merlin inhibition due to PAK1 amplification and overexpression. To identify receptor TKs regulated by PAK1, we performed a multiplex antibody-based assay that measures activated TKs and associated proteins in HMLE-PAK1 and HMLE-PAK1 K299R cells regardless of their mode of activation (Du et al., 2009) . We found that six TKs or associated proteins exhibited at least a significant 1.5fold increase in phosphotyrosine levels in HMLE-PAK1 cells when compared to HMLE-PAK1 K299R cells (Figure 6e ; Du et al., 2009) . Confirming our prior findings, ERK2, but not EGFR, scored in this assay. Interestingly, we found that three different MET-specific antibodies showed that MET phosphotyrosine levels were significantly elevated in HMLE cells expressing PAK1 compared to PAK1 K299R . Together, these observations strongly suggested that PAK1-mediated inhibition of merlin function led to activation of MET signaling rather than EGFR activation.
In HMLE-PAK1 cells, we found that MET was phosphorylated at Y1234/1235 and Y1003-sites associated with MET activation and trafficking (Figure 7a ; reviewed in Trusolino et al., 2010) . We also found that a MET adaptor protein, GAB1 (Weidner et al., 1996) , and a MET downstream effector molecule, STAT3 (Boccaccio et al., 1998) , were phosphorylated in HMLE-PAK1, providing strong evidence that MET signaling was activated by PAK1 overexpression (Figure 7a ). Moreover, when NF2 was overexpressed in HMLE-PAK1 cells, phosphorylation of PAK1 T423 decreased slightly, whereas that of MET Y1234/1235 was eliminated (Figure 7b ). Conversely, when NF2 was suppressed in HMLE cells, phosphorylation of MET was enhanced (Supplementary Figure 5A) .
To determine the contribution of MET signaling to PAK1-induced anchorage-independent growth, we treated HMLE-PAK1 and SUM52 with the MET inhibitor PHA-665752, which inhibits MET signaling through GAB1 (Christensen et al., 2003) . We found that PHA-665752 inhibited anchorage-independent growth of both HMLE-PAK1 and SUM52 in a dose-dependent manner (Figure 7c; Supplementary Figure 6A ).
When we introduced MET-or GAB1-specific shRNAs in HMLE-PAK1 and SUM52, we found that suppression of MET or GAB1 compromised anchorageindependent growth of both cell lines that are dependent on PAK1 for transformation ( Figure 7d ; Supplementary  Figures 6B and 6C ). These observations demonstrate that PAK1 regulates MET activity by modulating merlin, and that MET signaling through GAB1 is required for PAK1-driven anchorage-independent growth.
Inhibition or activation of MET signaling in HMLE derivatives by pharmacological or genetic methods did not alter phospho-ERK1/2 levels ( Supplementary Figures 5A and 5B) , indicating that MAPK activation and MET regulation through merlin are independent events regulated by PAK1 (Figure 8 ).
Discussion
MAPK pathway activation is common in breast cancers (reviewed in Santen et al., 2002) . In some cases, this activation is driven by amplification of ERBB2. However, a substantial proportion of breast cancers with normal ERBB2 copy number also show activation of MAPK signaling. Here, we used an experimental model of We screened 597 kinase-related ORFs and found PAK1 as a kinase whose expression induced anchorageindependent colony formation in HMLE cells. On the basis of these observations, we concluded that PAK1 is a transforming kinase, which may also cooperate with other oncogenic alterations, such as PI3K activation, to enhance transformation.
In parallel, although prior studies have reported amplifications of 11q13-q14, we used two largest collections of copy number data in human tumors currently available (Tumorscape and TCGA) to confirm that PAK1 is amplified in 30-33% of breast cancer and a significant proportion of other epithelial cancers. We further showed that breast cancer cell lines harboring PAK1 amplification are dependent on its expression for transformation but not proliferation. These observations substantiate PAK1 as the target gene in one of the two 11q13-14 amplicons and further define PAK1 as a bona fide breast cancer oncogene.
Through similar transformation and copy number analyses of group I PAKs, we found that PAK1 and PAK3, but not PAK2, promoted colony formation of HMLE cells. However, we failed to find significant amplification of PAK3 in Tumorscape (Supplementary Figure 1B, data not shown) . Hence, among its closest family members, PAK1 shows strongest oncogenic characteristics. PAK1 is known to regulate several signaling pathways. We found that PAK1-induced activation of both MAPK and MET signaling are essential for PAK1driven cell transformation. Although PAK1 also regulates LIMK1/2, the suppression of LIMK1/2 failed to affect anchorage-independent growth (data not shown). Furthermore, PAK1, as an effector of the small GTPases, RAC1 and CDC42, may regulate invasion or metastasis in some cellular contexts. Our observations, however, implicate PAK1 as an oncogene that induces transformation in breast and possibly other cancers. In addition, we found that two signaling pathways-MAPK and merlin-MET-were coordinately regulated by PAK1 to drive anchorage-independent growth. Using both genetic and pharmacological manipulations, we showed that anchorage-independent growth induced by PAK1 requires independent activation of MAPK as well as MET signaling. We have also observed that activation of the MAPK pathway by PAK1 is not specific to HMLE or SUM52 cells but also occurs in human mammary epithelial cells only expressing hTERT (HME), in which case the expression of PAK1 also enhances phosphorylation of ERK1/2 and transforms them ( Supplementary Figure 7) . As we and others have found that PAK1 expression is necessary for RAS-induced cell transformation, our observations also suggest that amplification of PAK1 is an alternative mechanism of activating MAPK signaling in human breast cancers.
Prior work showed that the tumor suppressor merlin regulates EGFR signaling. However, we failed to find any evidence using both focused and unbiased assays that PAK1-mediated regulation of merlin induced alterations in EGFR function. Instead, we found that PAK1 expression leads to activation of MET signaling, which was required for anchorageindependent growth. These findings established the contribution of MET signaling to PAK1-dependent transformation and demonstrated that merlin regulates multiple receptor TK signaling cascades in a similar manner.
The identification of PAK1 as a breast cancer oncogene provides one mechanism by which the MAPK pathway is activated in breast cancers that do not harbor amplifications of ERRB2 or oncogenic mutations in the RAS-RAF-MEK-ERK pathway. Although ERBB2 expression has been shown to correlate with PAK1 activation, (Arias-Romero et al., 2010) , indicating that they function in the same pathway, co-amplification of ERBB2 and PAK1 may not entirely be redundant. ERBB2 amplification can lead to activation of other RAS effector pathways in Our studies using previously characterized kinasedead PAK1-mutant allele (K299R) showed that PAK1 kinase activity is required for transformation, and establish PAK1 as a target for small-molecule inhibition in cancers that harbor PAK1 amplification. Our observations further indicate that breast cancer cell lines, such as SUM52 and SUM190, that harbor PAK1 amplification and exhibit correspondingly elevated expression levels are best examples of breast tumor derived cells that show oncogenic addiction to PAK1. Conversely, although HMLER cells did not show overexpression or elevated activity of PAK1, they were dependent on PAK1 for transformation, indicating that PAK1 can also behave as an essential gene in RASdriven cancers. In sum, we present evidence that PAK1 functions as a driving oncogene, a cooperating oncogene, as well as an essential non-oncogene that mediates transformation of mammary cells through regulation of multiple signaling pathways.
Materials and methods
Cell lines and reagents HMLE derivatives were cultured in Clonetics MEGM (Lonza, Basel, Switzerland). SUM52 and SUM190 were obtained from Stephen Ethier and cultured in a 50:50 mixture of mammary epithelial cell growth medium (MEGM) and DMEM/F12 (Invitrogen Carlsbad, CA, USA) with 10% inactivated fetal calf serum (Sigma-Aldrich, St Louis, MO, USA). SKBR3 and EFM19 were cultured in RPMI or RPMI (À) phenol red (Invitrogen), respectively, with 10% inactivated fetal calf serum. All media contained penicillin/streptomycin (Cellgro, Manassas, VA, USA). pBabe-Puro-Flag-PAK1 K299R was derived by site-directed mutagenesis of pBabe-Puro-Flag-PAK1 using QuikChange-IIXL (Stratagene, Santa Clara, CA, USA). Primer sequences are shown in Supplementary Table 1 . Retroviral and lentiviral production was carried out as previously described (Boehm et al., 2005; Moffat et al., 2006) . Infections were modified to incorporate spins at 1178 Â g (2250 r.p.m.) for 30 min at 25 1C. U0126 (EMD Biosciences, Gibbstown, NJ, USA) and PHA-665752 (Tocris, Ellisville, MO, USA) were reconstituted in dimethyl sulfoxide and added to cells while seeding in soft agar. shRNAs were obtained from the RNAi Consortium (TRC) at the Broad Institute; the corresponding reference numbers are as follows: shPAK1 no. 1-TRCN0000195500, shPAK1 no. 2-TRCN0000025258, shNF2 no. 1-TRCN0000039974, shNF2 no. 2-TRCN0000010397, shRAF1 no. 1-TRCN0000195502, shRAF1 no. 2-TRCN0000196969, shMET no. 1-TRCN0000199327, shMET no. 2-TRCN00-00009850, shGAB1 no. 1-TRCN0000074283 and shGAB1 no.
2-TRCN0000074285.
Pooled human kinase ORF screen The second-generation pBabe-Puro-Myr-Flag kinase ORF library was developed by the Center for Cancer Systems Biology at the Dana-Farber Cancer Institute and TRC (Johannessen et al., 2010) . This ORF library consists of 597 kinase-related ORFs that were pooled at equal DNA amounts in random order into 22 pools, each containing 25-27 ORFs. HMLEA was infected with virus produced from the DNA pools. Cells were then selected for puromycin resistance at 1 mg/ml. pBabe-Puro-MEK DD , diluted 1:25 with pBabe-Puro, and the parental vector pBabe-Puro were used as positive and negative controls, respectively. HMLEA cells expressing the pools or controls were seeded in 0.3% Noble agar (Sigma-Aldrich) in six-well plates, six replicate wells/pool, and assayed for colony formation. Bottom agar consisted of Dulbecco 0 s Modified Eagle's Medium (DMEM) with 0.6% Noble agar, 8% inactivated fetal calf serum and Antibiotic-Antimycotic (Invitrogen). Colony formation was assessed after 2 weeks when images of each well were taken at Â 6.25 magnification on Olympus SZX9 microscope with Olympus (Center Valley, PA, USA) Qcolor 3 camera using Magnafire or Q Capture and analyzed with ImageJ (Bethesda, MA, USA) software. Macroscopic colonies (4100 square pixels or 0.004 m) with the circularity of 0.5-1 were counted. Median colony number of the pools was calculated and those that scored 1.5 s.d.s above median were selected for further study. Colonies 450 square pixels (0.002 m) with the circularity of 0.8-1 were counted in all colony formation assays post screening.
Immunoblotting
For immunoblot analyses, samples were harvested in RIPA (Cell Signaling Technology (CST), Boston, MA, USA) or CLB (CST) with 1 mM phenylmethanesulfonyl fluoride (Sigma-Aldrich), protease inhibitor (Roche, Manheim, Germany) and phosphatase inhibitor (EMD Biosciences). Samples were run in 4-12% bis-tris gels (Invitrogen) in MOPS buffer (Invitrogen). Gels were transferred using the iBlot system (Invitrogen). For drug inhibition analysis by immunoblot, cells were treated overnight with dimethyl sulfoxide, U0126 or PHA-665752 at the indicated concentrations with constant total volume of dimethyl sulfoxide with or without drug. Antibodies used in the study were obtained from CST except for anti-EGFR, which was a gift from Jeonghee Cho, antimerlin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and 4G10 (Millipore, Temecula, CA, USA), Quantitative reverse transcriptase PCR RNA was harvested using QiaShredder and RNeasy (Qiagen, Valencia, CA, USA). Complementary DNA was prepared using Advantage RT-for-PCR (Clontech, Mountain View, CA, USA). Quantitative PCR was carried out using SYBR (Applied Biosystems, Beverly, MA, USA). The primers used are listed in Supplementary Table 1 .
Proliferation assay SUM52 expressing shRNAs against PAK1 or lacZ or HMLE expressing vector control or PAK1 were plated in triplicate in a six-well plates. Cells were counted the next day (day 1) as baseline and then counted and replated for 21 or 23 days at indicated time points to calculate population-doubling times.
Fluorescence in situ hybridization Fluorescence in situ hybridization was carried out as previously described (Knoll and Lichter, 2005) . Human chromosome 11 cep probe and BAC probe 11-381E5 (PAK1) were used. Hybridization signals were viewed on an Olympus BX-51 fluorescent microscope system.
Luminex assay
Lysates were harvested in normal growth conditions in MEGM. The Luminex assay was carried out for TKs and associated proteins as previously described (Du et al., 2009) . Raw data were normalized by subtracting antibody and sample backgrounds. One or more antibodies (analytes) against a specific TK or associated protein may be present. Average normalized signal of triplicates for each of the 244 Figure 8 PAK1 simultaneously activates two distinct signaling pathways to promote transformation. The model depicts PAK1 mechanism of action to activate the RAS-MAPK (orange) pathway through direct activation of RAF1 and MEK1. The second arm (purple) shows that PAK1 and merlin are in an inhibitory loop, which can be pushed by PAK1 amplification and overexpression to inhibit merlin that leads to MET signaling activation through GAB1. A full colour version of this figure is available at the Oncogene journal online.
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Y Shrestha et al analytes was calculated. Normalized signals of 10 or higher in HMLE-PAK1 and HMLE-PAK1 K299R were considered positive. Normalized signals for analytes in HMLE-PAK1 were divided by corresponding signals in HMLE-PAK1 K299R , and those with signal fold difference of 1.5 or higher were considered significantly increased.
Copy number analysis Tumorscape was analyzed as described (Beroukhim et al., 2010) . GISTIC profile for Tumorscape was created with all 3131 tumor samples and cancer cell lines including 243 breast samples. Copy number profiles were created for each cancer type with up to 80 samples that show PAK1 amplification. Breast samples with a score of 0.8 (log2 copy number ratio) or higher in Tumorscape were taken into consideration for the PAK1-CCND1 co-amplification study. GISTIC profile for TCGA breast invasive adenocarcinoma was created with 507 cancer samples.
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